Patents by Inventor Norio NONOMURA

Norio NONOMURA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220178932
    Abstract: An object of the invention is to provide a method for detecting cancer in a simple and highly accurate manner, and a reagent that can be used in the method. A method for detecting cancer (excluding renal cell cancer), which comprises measuring the level of Azurocidin (AZU1) in a sample, in which it is determined that cancer is detected when a measured value exceeds a preset reference value. The cancer is preferably selected from the group consisting of stomach cancer, breast cancer, colorectal cancer, and lung cancer. A reagent containing an antibody that specifically recognizes AZU1 is used in detecting cancer (excluding renal cell cancer).
    Type: Application
    Filed: April 15, 2020
    Publication date: June 9, 2022
    Applicants: JAPANESE FOUNDATION FOR CANCER RESEARCH, OSAKA UNIVERSITY, TOSOH CORPORATION
    Inventors: Koji UEDA, Naomi OHNISHI, Kazutake TSUJIKAWA, Norio NONOMURA, Motohide UEMURA, Kentaro JINGUSHI, Norihisa OHTAKE, Yasutoshi KAWAI
  • Publication number: 20220088064
    Abstract: One drug (preparation) of the present invention is a drug for a reproductive disorder containing a silicon fine particle, an aggregate of silicon fine particles or a crystal grain of silicon having a hydrogen-generating ability. Hydrogen generated from the silicon fine particle in the drug can contribute to the prevention and/or treatment of reproductive disorder.
    Type: Application
    Filed: November 29, 2019
    Publication date: March 24, 2022
    Applicant: OSAKA UNIVERSITY
    Inventors: Ryoichi IMAMURA, Hikaru KOBAYASHI, Yuki KOBAYASHI, Shinichiro FUKUHARA, Yusuke INAGAKI, Norio NONOMURA
  • Patent number: 11226334
    Abstract: [Problem] To provide a method for detecting high-risk prostate cancer, for the purpose of providing useful information, such as necessity of biopsy, to a test-positive patient in a PSA test. [Solution] The method for detecting high-risk prostate cancer according to the present invention comprises reacting a PSA contained in a sample composed of urine collected from a human body which is suspected to be suffering from prostate cancer with (1) a fucose ?1?6 affinitive lectin which has a characteristic property that the lectin has affinity expressed by a binding constant of 1.0×104 M?1 or more (at 25° C.) for an ?1?6 fucose sugar chain No. 405. The fucose ?1?6 affinitive lectin is preferably (2) a fucose ?1?6 specific lectin which has a characteristic property that the lectin has a binding constant of 1.0×104 M?1 or less (at 25° C.) for a sugar chain No. 003 that does not contain ?1?6 fucose and a glycolipid-type sugar chain No. 909 that does not contain ?1?6 fucose.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: January 18, 2022
    Assignees: J-CHEMICAL, INC., OSAKA UNIVERSITY
    Inventors: Yuka Kobayashi, Kazutoshi Fujita, Norio Nonomura, Eiji Miyoshi
  • Publication number: 20210275578
    Abstract: One drug (solid preparation) 100 of the present invention is a drug for a disease of kidney that contains a silicon fine particle, an aggregate of the silicon fine particles, or a crystal grain of silicon having a hydrogen-generating ability. Hydrogen generated from the silicon fine particle in the drug can contribute to the prevention and/or treatment of the kidney disease.
    Type: Application
    Filed: April 21, 2021
    Publication date: September 9, 2021
    Inventors: Hikaru KOBAYASHI, Yuki KOBAYASHI, Ryoichi IMAMURA, Norio NONOMURA
  • Patent number: 11103527
    Abstract: One drug (solid preparation) 100 of the present invention is a drug for a disease of kidney that contains a silicon fine particle, an aggregate of the silicon fine particles, or a crystal grain of silicon having a hydrogen-generating ability. Hydrogen generated from the silicon fine particle in the drug can contribute to the prevention and/or treatment of the kidney disease.
    Type: Grant
    Filed: July 4, 2018
    Date of Patent: August 31, 2021
    Assignee: Osaka University
    Inventors: Hikaru Kobayashi, Yuki Kobayashi, Ryoichi Imamura, Norio Nonomura
  • Publication number: 20210115148
    Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.
    Type: Application
    Filed: December 28, 2020
    Publication date: April 22, 2021
    Applicants: Shionogi & Co., Ltd., Osaka University
    Inventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
  • Publication number: 20210047421
    Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.
    Type: Application
    Filed: October 30, 2020
    Publication date: February 18, 2021
    Applicants: Shionogi & Co., Ltd., Osaka University
    Inventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
  • Publication number: 20200264182
    Abstract: [Problem] To provide a method for detecting prostate cancer, the method having a higher degree of certainty than the PSA blood test and providing measurement values that correlate with risk classification. [Solution] This method for detecting prostate cancer is characterized in that: the method includes reacting fucose ?1?6 specific lectin and fucosylated PSA contained in a sample constituted of serum collected from a subject, and detecting the reacted lectin; and the pH in at least one step of the group consisting of the reaction step for reacting the fucosylated PSA and the lectin and processing steps thereafter is adjusted to above 8.5 and less than 11.0.
    Type: Application
    Filed: September 21, 2018
    Publication date: August 20, 2020
    Inventors: Kazutoshi FUJITA, Norio NONOMURA, Eiji MIYOSHI, Yuka KOBAYASHI
  • Publication number: 20200232973
    Abstract: The disclosure provides a method of measuring an efficacy of a drug composition for cancer and a method for treating a cancer by administering to a subject an effective amount of a pharmaceutical composition having a polypeptide that binds to a peptide produced by cDNA of GenBank ACC No. NM_005201.3 or NM_007720.2.
    Type: Application
    Filed: January 2, 2020
    Publication date: July 23, 2020
    Applicants: Shionogi & Co., Ltd., Osaka University
    Inventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
  • Publication number: 20200222463
    Abstract: The disclosure provides a pharmaceutical composition with a polypeptide that binds to a peptide produced by cDNA of GenBank ACC No. NM_005201.3 or NM_007720.2, and methods of use thereof.
    Type: Application
    Filed: January 2, 2020
    Publication date: July 16, 2020
    Applicants: Shionogi & Co., Ltd., Osaka University
    Inventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
  • Publication number: 20200179439
    Abstract: One drug (solid preparation) 100 of the present invention is a drug for a disease of kidney that contains a silicon fine particle, an aggregate of the silicon fine particles, or a crystal grain of silicon having a hydrogen-generating ability. Hydrogen generated from the silicon fine particle in the drug can contribute to the prevention and/or treatment of the kidney disease.
    Type: Application
    Filed: July 4, 2018
    Publication date: June 11, 2020
    Inventors: Hikaru KOBAYASHI, Yuki KOBAYASHI, Ryoichi IMAMURA, Norio NONOMURA
  • Patent number: 10550191
    Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: February 4, 2020
    Assignees: Shionogi & Co., Ltd., Osaka University
    Inventors: Tetsuya Yoshida, Yujiro Kidani, Mitsunobu Matsumoto, Takayuki Kanazawa, Satomi Shinonome, Kanji Hojo, Naganari Ohkura, Shimon Sakaguchi, Atsushi Tanaka, Hisashi Wada, Atsunari Kawashima, Norio Nonomura
  • Publication number: 20190310258
    Abstract: Provided is a method wherein an affected tissue and a normal tissue obtained from the vicinity of the affected tissue are left at rest in a culture medium, and a disease-specific biomarker is searched for in an exudate therefrom. A biomarker specific to renal cell carcinoma has been found by this method.
    Type: Application
    Filed: October 26, 2017
    Publication date: October 10, 2019
    Applicants: JAPANESE FOUNDATION FOR CANCER RESEARCH, OSAKA UNIVERSITY
    Inventors: Koji Ueda, Naomi Ohnishi, Norio Nonomura, Motohide Uemura, Kazutoshi Fujita, Kazutake Tsujikawa, Kentarou Jingushi
  • Publication number: 20190071508
    Abstract: The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.
    Type: Application
    Filed: November 7, 2018
    Publication date: March 7, 2019
    Applicants: SHIONOGI & CO., LTD., OSAKA UNIVERSITY
    Inventors: Tetsuya YOSHIDA, Yujiro KIDANI, Mitsunobu MATSUMOTO, Takayuki KANAZAWA, Satomi SHINONOME, Kanji HOJO, Naganari OHKURA, Shimon SAKAGUCHI, Atsushi TANAKA, Hisashi WADA, Atsunari KAWASHIMA, Norio NONOMURA
  • Publication number: 20190049451
    Abstract: [Problem] To provide a method for detecting high-risk prostate cancer, for the purpose of providing useful information, such as necessity of biopsy, to a test-positive patient in a PSA test. [Solution] The method for detecting high-risk prostate cancer according to the present invention comprises reacting a PSA contained in a sample composed of urine collected from a human body which is suspected to be suffering from prostate cancer with (1) a fucose ?1?6 affinitive lectin which has a characteristic property that the lectin has affinity expressed by a binding constant of 1.0×104 M?1 or more (at 25° C.) for an ?1?6 fucose sugar chain No. 405. The fucose ?1?6 affinitive lectin is preferably (2) a fucose ?1?6 specific lectin which has a characteristic property that the lectin has a binding constant of 1.0×104 M?1 or less (at 25° C.) for a sugar chain No. 003 that does not contain ?1?6 fucose and a glycolipid-type sugar chain No. 909 that does not contain ?1?6 fucose.
    Type: Application
    Filed: February 3, 2017
    Publication date: February 14, 2019
    Applicants: J-Oil Mills, Inc., Osaka University
    Inventors: Yuka KOBAYASHI, Kazutoshi FUJITA, Norio NONOMURA, Eiji MIYOSHI